Induction of potent antitumour natural-killer cells from peripheral blood of patients with advanced prostate cancer

BJU International

Volumn 92, Issue 9, 2003, Pages 1009-1015

  Oikawa, T ^a,b   Kawai, K ^a   Ishiwata, I ^c   Ohno, T ^b   Akaza, H ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b RIKEN   (Japan)

^c Ishiwata Obstet and Gynecol Hosp   (Japan)

Author keywords

Cell therapy; Human natural killer cells; Prostate cancer; Refractory; Selective expansion

Indexed keywords

INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD AUTOTRANSFUSION; CANCER CELL; CANCER CELL CULTURE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TISSUE THERAPY;

EID: 0346119082     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2003.04509.x     Document Type: Article

References (25)

1. Small EJ. Update on the diagnosis and treatment of prostate cancer. Curr Opin Oncol 1998; 10: 244-52
2. Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989; 7: 601-24
3. Blades RA, Keating PJ, McWilliam LJ, George NJR, Stern PL Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995; 46: 681-7
4. Sanda MG, Restifo NP, Walsh JC et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995; 87: 280-5
5. Bander NH, Yao D, Liu H et al. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 1997; 33: 233-9
6. Lu QL, Abel P, Mitchell S, Foster C, Lalani EN. Decreased HLA-A expression in prostate cancer is associated with normal allele dosage in the majority of cases. J Pathol 2000; 190: 169-76
7. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421-38
8. Herberman RB et al. Lymphokine-activated killer cell activity. Characteristics of effector cells and their progenitors in blood and spleen. Immunol Today 1987; 8: 178-81
9. Melder RJ, Walker ER, Herberman RB, Whiteside TL. Surface characteristics, morphology, and ultrastructure of human adherent lymphokine-activated killer cells. J Leukoc Biol 1990; 48: 163-73
10. Ishiwata I, Ono I, Ishiwata C et al. Carcinoembryonic proteins produced by Wilms' tumor cells in vitro and in vivo. Exp Pathol 1991; 41: 1-9
11. Harada H, Saijo K, Watanabe S et al. Selective expansion of human natural killer cells from peripheral blood mononuclear cells by the cell line, HFWT. Jpn J Cancer Res 2002; 93: 313-9
12. Schellhammer PF, Bracken RB, Bean MA et al. The immune evaluation with skin testing: a study of testicular, prostatic and bladder neoplasms. Cancer 1976; 38: 149-53
13. Kawai K, Sasaki T, Saijo-Kurita K, Akaza H, Koiso K, Ohno T. Additive effects of antitumor drugs and lymphokine-activated killer cell cytotoxic activity in tumor cell killing determined by lactate-dehydrogenase-release assay. Cancer Immunol Immunother 1992; 35: 225-9
14. Liu SQ, Saijo K, Todoroki T, Ohno T. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Nature Med 1995; 1: 267-71
15. Kim C, Matsumura M, Saijo K, Ohno T. In vitro induction of HLA-A2402-restricted and carcinoembryonic-antigen-specific cytotoxic T lymphocytes on fixed autologous peripheral blood cells. Cancer Immunol Immunother 1998; 47: 90-6
16. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-4
17. Xue BH, Zhang Y, Sosman JA, Peace DJ. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 1997; 30: 73-8
18. + cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998; 36: 129-38
19. Tjoa BA, Simmons SJ, Bowes VA et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998; 36: 39-44
20. Dannull J, Diener PA, Prikler L et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000; 60: 5522-8
21. Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 2001; 250: 462-75
22. Suzuki K, Nakazato H, Matsui H et al. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3, immunogenetherapy using a highly secretable form of interleukin-15 gene transfer. J Leukoc Biol 2001; 69: 531-7
23. Lahat N, Alexander B, Levin DR, Moskovitz B. The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate. Cancer Immunol Immunother 1989; 28: 208-12
24. Kastelan M, Kraljic I, Tarle M. NK cell activity in treated prostate cancer patients as a probe for circulating tumor cells: Hormone regulatory effects in vivo. Prostate 1992; 21: 111-20
25. Falk CS, Noessner E, Weiss EH, Schendel DJ. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells. Cancer Res 2002; 62: 480-7